Methacrylate micro/nano particles prepared by spray drying: a preliminary in vitro/in vivo study

Figures & data

Table 1. Batch specifications of micro/nanoparticles.

Formulation code	Drug:Polymer (w/w)	Eudragit®	CF	Ethanol
1	2:1	500 mg ERS	1 g	100 ml
2	2:1	500 mg ERL	1 g	100 ml
3	2:1	250 mg ERS+ 250 mg ERL	1 g	100 ml
4	1:1	1 g ERS	1 g	100 ml
5	1:1	1 g ERL	1 g	100 ml
6	1:1	500 mg ERS+ 500 mg ERL	1 g	100 ml
7	1:2	2 g ERS	1 g	100 ml
8	1:2	2 g ERL	1 g	100 ml
9	1:2	1 g ERS+1 g ERL	1 g	100 ml

Table 2. Microparticles physical tests.

Formulation code	Drug:polymer (w/w)	Yield %	Encapsulation efficiency (%)	Particle size (µm)
1	2:1	8.74	58.82	208.930–239.883
2	2:1	44.75	65.31	26.306–30.200
3	2:1	71.56	84.9	17.378–19.953
4	1:1	72.05	80.45	3.802–4.365
5	1:1	70.05	63.74	3.311–3.802
6	1:1	73.50	67.8	4.365–5.012
7	1:2	65.52	51.15	3.802–4.365
8	1:2	71.91	42.73	3.802–4.365
9	1:2	69.15	39.99	4.365–5.012

Figure 1. ESEM photographs of microparticles obtained by spray drying containing ERL with 1:2 ratio drug:polymer (formulation 8).

Figure 2. In vitro drug release of the microparticles with (a) ERS, (b) ERL and (c) mixture of ERS and ERL (1:1 w/w) expressed as a percentage of the amount of total drug content.

Figure 3. In vitro drug release of the microparticles with 1:2 drug:polymer ratio for 48 h expressed as a percentage of the amount of total drug content.

Figure 4. Plasma concentrations of ciprofloxacin versus time after administration of a 212-mg oral dose of ciprofloxacin HCl and 500 mg loaded microparticles.

Figure 5. Cumulative permeation of crude ciprofloxacin HCl and Cipro-loaded microparticles through noneverted rat intestine in Ringer’s buffer medium at 37 °C.